[HTML] mdpi.com

[HTML][HTML] Scientific rationale for combined immunotherapy with PD-1/PD-L1 antibodies and VEGF inhibitors in advanced hepatocellular carcinoma

M Kudo - Cancers, 2020 - mdpi.com
A successful phase III trial for the combination of atezolizumab and bevacizumab (the
IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is …
被引用次数：163 相关文章

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.

M Kudo - Cancers, 2020 - europepmc.org
A successful phase III trial for the combination of atezolizumab and bevacizumab (the
IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is …

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

M Kudo - Cancers, 2020 - cir.nii.ac.jp
抄録< jats: p> A successful phase III trial for the combination of atezolizumab and
bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently …
[PDF] semanticscholar.org

[PDF][PDF] Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

M Kudo - pdfs.semanticscholar.org
A successful phase III trial for the combination of atezolizumab and bevacizumab (the
IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is …
[HTML] nih.gov

[HTML][HTML] Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

M Kudo - Cancers, 2020 - ncbi.nlm.nih.gov
A successful phase III trial for the combination of atezolizumab and bevacizumab (the
IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is …

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.

M Kudo - Cancers, 2020 - search.ebscohost.com
A successful phase III trial for the combination of atezolizumab and bevacizumab (the
IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is …

Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma

M Kudo - Cancers, 2020 - pubmed.ncbi.nlm.nih.gov
A successful phase III trial for the combination of atezolizumab and bevacizumab (the
IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is …